D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease

Journal of Clinical Investigation

Volumn 112, Issue 6, 2003, Pages 892-901

  Tieu, Kim ^a   Perier, Celine ^a   Caspersen, Casper ^a   Teismann, Peter ^a   Wu, Du Chu ^a   Yan, Shi Du ^a   Naini, Ali ^a   Vila, Miquel ^a   Jackson Lewis, Vernice ^a   Ramasamy, Ravichandran ^a   Przedborski, Serge ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 HYDROXYBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROGEN PEROXIDE; HYDROXYBUTYRATE DEHYDROGENASE; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDIZING AGENT; OXIDOREDUCTASE; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; IMMUNOBLOTTING; MALE; MESENCEPHALON; MITOCHONDRIAL RESPIRATION; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; BRAIN; C57BL MOUSE; CELL RESPIRATION; CYTOLOGY; DRUG EFFECT; ELECTRON TRANSPORT; HUMAN; METABOLISM; MITOCHONDRION; MOTOR ACTIVITY; NERVE CELL; PHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3-HYDROXYBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; ANIMALS; BRAIN; CELL RESPIRATION; DOPAMINE; DOPAMINE AGENTS; ELECTRON TRANSPORT; ELECTRON TRANSPORT COMPLEX I; HUMANS; HYDROGEN PEROXIDE; HYDROXYBUTYRATE DEHYDROGENASE; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MOTOR ACTIVITY; NAD; NADH, NADPH OXIDOREDUCTASES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDANTS; OXYGEN; PARKINSON DISEASE; TYROSINE 3-MONOOXYGENASE;

EID: 0142217904     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318797     Document Type: Article

References (48)

1. Przedborski, S., Vila, M., and Jackson-Lewis, V. 2003. Neurodegeneration: what is it and where are we? J. Clin. Invest. 111:3-10. doi: 10.1172/JCI200317522.
2. Fahn, S., and Przedborski, S. 2000. Parkinsonism. In Merritt's neurology. L.P. Rowland, editor. Lippincott Williams & Wilkins. New York, New York, USA. 679-693.
3. Przedborski, S., Kostic, V., Giladi, N., and Eidelberg, D. 2003. Dopaminergic system in Parkinson's disease. In Dopamine receptors and tranporters. A. Sidhu, M. Laruelle, and P. Vernier, editors. Marcel Dekker Inc. New York, New York, USA. 363-402.
4. Nicklas, W.J., Yougster, S.K., Kindt, M.V., and Heikkila, R.E. 1987. MPTP, MPP+ and mitochondrial function. Life Sci. 40:721-729.
5. Langston, J.W., Ballard, P., and Irwin, I. 1983. Chronic parkinsonism in humans due co a product of meperidine-analog synthesis. Science. 219:979-980.
6. Greenamyre, J.T., Sherer, T.B., Betarbet, R., and Panov, A.V. 2001. Complex I and Parkinson's disease. IUBMB Life. 52:135-141.
7. Schapira, A.H., et al. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:823-827.
8. Parker, W.D., Jr., Boyson, S.J., and Parks, J.K. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:719-723.
9. Haas, R.H., et al. 1995. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37:714-722.
10. Swerdlow, R.H., et al. 1996. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40:663-671.
11. Guzman, M., and Blazquez, C. 2001. Is there an astrocyte-neuron ketone body shuttle? Trends Endocrinol. Metab. 12:169-173.
12. Owen, O.E., et al. 1967. Brain metabolism during fasting. J. Clin. Invest. 46:1589-1595.
13. Izumi, Y., Ishii, K., Karsuki, H., Benz, A.M., and Zorumski, C.F. 1998. β-Hydroxybutyrate fuels synaptic function during development. Histological and physiological evidence in rat hippocampal slices. J. Clin. Invest. 101:1121-1132.
14. Kashiwaya, Y., et al. 2000. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 97:5440-5444.
15. Liberatore, G., et al. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat. Med. 5:1403-1409.
16. Teismann, P., et al. 2003. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 100:5473-5478.
17. Yan, S.D., et al. 2000. Amyloid beta-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress. J. Biol. Chem. 275:27100-27109.
18. Przedborska, S., et al. 1996. Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 93:4565-4671.
19. Przedborski, S., et al. 1992. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-terrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1658-1667.
20. Ramsay, R.R., and Singer, T.P. 1986. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261:7585-7587.
21. Vyas, I., Heikkila, R.E., and Nicklas, W.J. 1986. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 46:1501-1507.
22. Liu, Y., Fiskum, G., and Schubert, D. 2002. Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80:780-787.
23. Votyakova, T.V., and Reynolds, I.J. 2001. Delta-Psi(m)-dependent and -independent production of reactive oxygen species by rat brain mitochondria. J. Neurochem. 79:266-277
24. Birch-Machin, M.A., and Turnbull, D.M. 2001. Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol. 65:97-117.
25. Brouillet, E., et al. 1998. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70:794-805.
26. Vila, M., et al. 2001. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98:2837-2842.
27. Rozas, G., López-Martín, E., Guerra, M.J., and Labandeira-García, J.L. 1998. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods. 83:165-175.
28. Wallace, T.M., Meston, N.M., Gardner, S.G., and Matthews, D.R. 2001. The hospital and home use of a 30-second hand-held blood ketone meter: guidelines for clinical practice. Diabet. Med. 18:640-645.
29. Sokoloff, L. 1973. Metabolism of ketone bodies by the brain. Annu. Rev. Med. 24:271-280.
30. Giovanni, A., Sieber, B.A., Heikkila, R.E., and Sonsalla, P.K. 1991. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257:691-697.
31. Javitch, J.A., D'Amato, R.J., Strittmatter, S.M., and Snyder, S.H. 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci U. S. A. 82:2173-2177.
32. Brown, G.C., Lakin-Thomas, P.L., and Brand, M.D. 1990. Control of respiration and oxidative phosphorylation in isolated rat liver cells. Eur. J. Biochem. 192:355-362.
33. Lai, J.C., and Clark, J.B. 1979. Preparation of synaptic and nonsynaptic mitochondria from mammalian brain. Methods Enzymol. 55:51-60.
34. Nicklas, W.J., Vyas, I., and Heikkila, R.E. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP. Life Sci. 36:2503-2508.
35. Bilger, A., and Nehlig, A. 1992. Quantitative histochemical changes in enzymes involved in energy metabolism in the rat brain during postnatal development. II. Glucose-6-phosphate dehydrogenase and beta-hydroxybutyrate dehydrogenase. Int. J. Dev. Neurosci. 10:143-152.
36. Zhang, W.W., Churchill, S., and Churchill, P. 1989. Developmental regulation of D-beta-hydroxybutyrate dehydrogenase in rat liver and brain. FEBS Lett. 256:71-74.
37. Jackson-Lewis, V., Jakowec, M., Burke, R.E., and Przedborski, S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:257-269.
38. Heikkila, R.E., Manzino, L., Cabbat, F.S., and Duvoisin, R.C. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 311:467-469.
39. Przedborski, S., and Vila, M. 2003. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 991:189-198.
40. Brown, G.C. 1992. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem. J. 284:1-13.
41. Mandir, A.S., et al. 1999. Poly (ADP-ribose) polymerase activation mediates MPTP-induced parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 96:5774-5779.
42. Cosi, C., and Marien, M. 1998. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res. 809:58-67.
43. Matthews, R.T., et al. 1999. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157:142-149.
44. Tennyson, V.M., Heikkila, R., Mytilineou, C., Cote, L., and Cohen, G. 1974. 5-Hydroxydopamine 'tagged' neuronal boutons in rabbit neostriatum: interrelationship between vesicles and axonal membrane. Brain Res. 82:341-348.
45. Chan, P., DeLanney, L.E., Irwin, I., Langston, J.W., and Di Monte, D. 1991. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57:348-351.
46. Anson, R.M., et al. 2003. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc. Natl. Acad. Sci. U. S. A. 100:6216-6220.
47. Duan, W., and Mattson, M.P. 1999. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 57:195-206.
48. Plecko, B., et al. 2002. Oral beta-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring of beta-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy. Pediatr. Res. 52:301-306.